# Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects

> **NCT00295022** · PHASE4 · COMPLETED · sponsor: **UCB S.A. - Pharma Sector** · enrollment: 418 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** Placebo
- **DRUG:** Montelukast
- **DRUG:** Levocetirizine

## Key facts

- **NCT ID:** NCT00295022
- **Lead sponsor:** UCB S.A. - Pharma Sector
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-29
- **Primary completion:** 2006-10-01
- **Final completion:** 2006-10-01
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295022, "Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00295022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*